1.17. Analysis.
Comparison 1: Medications compared with placebo, Outcome 17: Secondary: Impulsivity at end of treatment (continuous outcomes, MDs)
Comparison 1: Medications compared with placebo, Outcome 17: Secondary: Impulsivity at end of treatment (continuous outcomes, MDs)